JamaicaTuberculosis profile
Population  2014 2.8 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–0.01) 0.31 (0.26–0.38)
Mortality (HIV+TB only) <0.01 (<0.01–0.011) 0.32 (0.25–0.41)
Prevalence  (includes HIV+TB) 0.17 (0.087–0.27) 5.9 (3.1–9.6)
Incidence  (includes HIV+TB) 0.13 (0.11–0.16) 4.7 (3.8–5.7)
Incidence (HIV+TB only) 0.029 (0.023–0.036) 1.1 (0.84–1.3)
         
Case detection, all forms (%) 66 (55–81)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.4 (0.06–13) 0 (0–0)
MDR-TB cases among notified pulmonary
TB cases
2 (0–10) 0 (0–0)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 34   2
Pulmonary, clinically diagnosed 44   0
Extrapulmonary 6   0
       
Total new and relapse 86    
Previously treated, excluding relapses 0    
Total cases notified 86    
Among 86 new and relapse cases:
8 (9%) cases aged under 15 years; male:female ratio: 3.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 34 (100%) 2 (100%) 36
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 79 (92)
HIV-positive TB patients 19 (24)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 18 (95)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (77) 104
Previously treated cases, excluding relapse, registered in 2013   0
HIV-positive TB cases, all types, registered in 2013 (81) 16
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.1
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) <1
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-06-30 Data: www.who.int/tb/data